Shandong Linuo Pharmaceutical Packaging (301188.SZ) controlling shareholders and specific shareholders plan to reduce their holdings by a total of no more than 4% of shares.
Linuo Pharmaceutical Package (301188.SZ) announced that its shareholder Linuo Investment Holdings Group Co., Ltd. (hereinafter referred to as "Linuo Investment") intends to reduce its holdings of company shares through block trading within three months after the disclosure of the "Pre-Disclosure Announcement on the Reduction Plan of the Controlling Shareholder, Specific Shareholders, and Their Consistent Actors," which took place 15 trading days after the announcement date (from September 30, 2026, to December 29, 2026, excluding periods where reduction is prohibited by laws and regulations). The reduction will not exceed 5,189,100 shares, accounting for 2.00% of the company's total share capital.
Shandong Linuo Pharmaceutical Packaging (301188.SZ) announced that its shareholder Linuo Investment Holding Group Co., Ltd. (hereinafter referred to as "Linuo Investment") plans to reduce its holdings of the company's shares by no more than 5.1891 million shares, accounting for 2.00% of the company's total capital, through block trading within three months after the disclosure date of the "Pre-disclosure Announcement on the Shareholding Reduction Plan of the Controlling Shareholder, Specific Shareholders, and Their Concerted Actors" (from September 30, 2026, to December 29, 2026, excluding the period during which reduction is prohibited by laws and regulations).
Shareholder Jinan Caijin Fuxing Weishi Equity Investment Fund Partnership (Limited Partnership) (hereinafter referred to as "Fuxing Weishi") and its concerted actioner Ningbo Meishan Free Trade Port Area Fuxing Weiying Equity Investment Fund Partnership (Limited Partnership) (hereinafter referred to as "Fuxing Weiying") plan to collectively reduce their holdings of the company's shares by no more than 5.1891 million shares, accounting for 2.00% of the company's total capital, through centralized bidding and block trading within three months after the disclosure date of the pre-disclosure announcement (from September 30, 2026, to December 29, 2026, excluding the period during which reduction is prohibited by laws and regulations).
Related Articles

BIOHEART-B(02185) has appointed GIORGIO GOBBI as Vice President of Global Therapeutic Development at Antong.

Dencare (001328.SZ) indirect controlling shareholders concerted action party intends to reduce its holdings by no more than 1.74%.

POLY XVERSE IT (00209): Zhao Kai resigns as Chairman and Executive Director
BIOHEART-B(02185) has appointed GIORGIO GOBBI as Vice President of Global Therapeutic Development at Antong.

Dencare (001328.SZ) indirect controlling shareholders concerted action party intends to reduce its holdings by no more than 1.74%.

POLY XVERSE IT (00209): Zhao Kai resigns as Chairman and Executive Director

RECOMMEND





